Kangtai Bio | Briefing, News, Analysis, Research, Data

Kangtai Bio

Kangtai Bio a famous international pharmaceutical company

Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Sept 8, 1992

HQ location

Guangdong, China

Legal name

Shenzhen Kangtai Biological Products Co., Ltd.

Website

http://www.biokangtai.com/

office@biokangtai.com

Employees

501-1000

All
News
Analysis
Research

Briefing Feb 16, 2023 12:51 PM · Healthcare

Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A

Briefing Feb 07, 2023 12:11 PM · Healthcare

ForLong Biotech Nets Over CNY 100 Mn in Series A

In-depth

Healthcare

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Feb 02, 2023 10:45 AM

Briefing Feb 07, 2023 10:59 AM · Healthcare

CytoCan Corp. Nets CNY 10 Mn in Seed Round

Briefing Jan 30, 2023 10:44 AM · Healthcare

Levostar Completes Pre-A Financing Round to Further Invest in CGT

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Technology, Healthcare, Financials

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Briefing Jan 18, 2023 10:59 AM · Healthcare

BlissBio Nets Over CNY 100 Mn in Series B+

Briefing Jun 27, 2022 06:44 PM · Technology | Healthcare

Zhongxin fluoromaterials: it is planned to acquire 51% equity of Jiangxi Exxon through equity transfer and cash capital increase

Briefing Jan 28, 2022 07:49 PM · Technology | Healthcare

Kangtai biology: the net profit in 2021 is expected to increase by 76.68% - 106.13% year-on-year

Briefing Jan 23, 2022 05:59 PM · Healthcare

Kangtai biology: CDE starts the on-site verification of the registration of freeze-dried human rabies vaccine (human diploid cells)

Healthcare

HealthGuard: Registration of Indonesian Subsidiary, Investment in Producing HPV Vaccine

Jun 20, 2024 03:12 PM

Healthcare

SINOVAC Plans to Invest USD 100 Mn in Brazil Starting This Year

EqualOcean has learned that on June 4, Vice President of the Federative Republic of Brazil and Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, met with SINOVAC(科兴) Chairman, President, and CEO Yin Weidong(尹卫东) in Beijing.

Jun 06, 2024 06:18 PM

Briefing Sep 17, 2021 02:24 PM · Technology | Consumer Staples

Before the festival, the market of "drinking and taking medicine" reappeared, and the food and beverage ETF (515170) rose 2.5%

Briefing Sep 17, 2021 12:03 PM · Technology | Healthcare

2021 China Internet development innovation and investment competition (Changsha) public welfare project and Beidou Innovation Application Challenge kicked off

Briefing Sep 05, 2021 05:52 PM · Healthcare | Financials

Anxin strategy: high prosperity configuration and low position trading

Healthcare

Yilite Technology Completes A+ Round Financing of CNY 100 Million

Yilite Technology has secured over CNY 100 million in two rounds of financing within the year.

May 15, 2024 03:21 PM

Healthcare

Cellatopia Secures Nearly CNY Ten Mn in Seed Funding

EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).

Apr 18, 2024 01:25 PM

Briefing Aug 06, 2021 01:08 PM · Technology | Healthcare | Financials

Will Huawei's server business be packaged for sale? Huawei insiders: business is affected but will not give up

Briefing Jul 23, 2021 10:13 AM · Healthcare

Pharmaceutical and biological stocks fell sharply in early trading

Briefing Jul 19, 2021 05:45 PM · Technology | Healthcare | Financials

Samsung Xincai replied to the regulatory letter: there is no direct or indirect misappropriation of raised funds through entrusted loans

Briefing May 26, 2021 10:06 AM · Healthcare | Financials

Vaccine stocks weakened in early trading

EqualOcean Analysis